Home | Bionomics – Clinical-stage biopharmaceutical company
Bionomics is a global, clinical-stage biotechnology company focused on developing novel, first-in-class, ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders.
Bionomics Limited (BNOX) - Yahoo Finance
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia.
Bionomics Limited (BNOX): Stock Soars Over 162% Following …
2024年11月5日 · Bionomics Limited (Nasdaq: BNOX), a clinical-stage biotechnology company based in Australia and the U.S., has become a focal point in the biotech sector as its stock surged by an impressive 162.78%, trading at $0.5047 as of midday on November 4, 2024.
Bionomics - Wikipedia
Bionomics (Greek: bio = life; nomos = law) has two different meanings: the first is the comprehensive study of an organism and its relation to its environment. As translated from the French word Bionomie , its first use in English was in the period of 1885–1890.
Bionomics Announces Successful End-of-Phase 2 Meeting with …
2024年7月31日 · We believe BNC210 can potentially transform the standard-of-care in PTSD, a serious disorder impacting about 7% of Americans during their lifetime. Followings the recent initiation of the Phase 3...
Bionomics Announces Positive Topline Results from the Phase
2023年9月28日 · Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social...
Bionomics Limited Announces Private Placement of up to $70.0 …
2024年5月31日 · ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing...
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with
2024年7月18日 · Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious...
Bionomics Provides a Review of 2023 and of 2024 Plans
2024年1月22日 · Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social...
Bionomics Receives Milestone Payment of AUS$1M from Carina …
2024年11月4日 · Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious...